laurabbook@gmail.com

*September 2021* Note  MET can be a resistance mechanism to Tagrisso In this video, Dr Felip discusses the most recent efficacy data from ASCO 2021 on the use of MET inhibitors in NSCLC. View the video here. In this interview Dr Felip answers the following questions: How significant is MET as a therapeutic target…

*September 2021* From Blueprint Medicines:  Currently, there are no approved therapies for patients with osimertinib-resistant EGFRm NSCLC, and there is an urgent need for new therapies to address tumor resistance. BLU-945 was designed to potently inhibit triple-mutant EGFR harboring either the activating L858R or exon 19 deletion mutations combined with…

*August 2021* A discussion on how this variant of NSCLC differs from the (exon 19 and exon 21) EGFR mutations and the demographics of EGFR patients. View the entire transcript or watch the video here. Alexander I. Spira, MD, PhD, FACP: I know we talked a little bit about this before,…

*August 2021* There have been many discussions in our EGFR Resisters Facebook group regarding the use of immunotherapy in EGFR+ lung cancer. Three lung cancer doctors weigh in: Read more. And here is Dr. Ross Camidge on the topic: Read more.

*August 2021* In this video, Dr. David Carbone talked about the promise and successes of targeted therapies and immunotherapy, answered questions about oncogene mutations and available treatments, and outlined current studies that could be game-changers for lung cancer patients. Watch the video here.

*August 2021* Introduction Management of central nervous system (CNS) metastases in patients with driver-mutated NSCLC has traditionally incorporated both tyrosine kinase inhibitors (TKIs) and intracranial radiation. Whether next generation, CNS-penetrant TKIs can be used alone without upfront radiation, however, remains unknown. This multi-institutional retrospective analysis aimed to compare outcomes in…

*January 2021* The ATOMIC consortium is a group of thoracic oncologists from North America. They received funding from AstraZeneca to build a registry of patients with EGFR+ NSCLC. The registry contains all treatments given, molecular tests performed, and radiologic results.The registry contains data on 1187 patients with EGFR+ NSCLC. This…

*January 2021* Patritumab deruxtecan demonstrated early and clinically meaningful activity in pretreated patients with metastatic or unresectable EGFR-mutant non–small cell lung cancer in the results of a phase 1 trial that were presented during the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore.…